Conmed (CNMD) Tops Q4 EPS by 1c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
CONMED (CNMD) PT Lowered to $79 at Needham & Company
January 23, 2019 7:34 AM ESTNeedham & Company analyst Mike Matson lowered the price target on CONMED (NASDAQ: CNMD) to $79.00 (from $86.00) while maintaining a Buy rating.
The analyst commented, "CNMD's 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that... More



